PRVL News and Press, Prevail Therapeutics Inc. From 09/18/20

NEW YORK, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chie...

Quick Take Inhibikase Therapeutics ( IKT ) intends to raise $25 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is advancing a pipeline of treatment candidates for neurodegenerative and cancer diseases. IKT is still at a ...

The following slide deck was published by Prevail Therapeutics Inc. in conjunction with this Read more ...

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc.  (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced the appointment of William H. Carson, ...

NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the Company will participate in the followi...

Prevail Therapeutics Inc. (PRVL) Q2 2020 Results Earnings Conference Call August 11, 2020, 07:30 AM ET Company Participants Asa Abeliovich - CEO & Founder Brett Kaplan - Chief Financial Officer Jeffrey Sevigny - Chief Medical Officer Conference Call Participants Jeffrey...

The following slide deck was published by Prevail Therapeutics Inc. in conjunction with their 2020 Q2 earnings Read more ...

Prevail Therapeutics (NASDAQ: PRVL ) : Q2 GAAP EPS of -$0.66 misses by $0.09 . More news on: Prevail Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Preliminary Data Demonstrates Normalization of CSF GBA1 Enzyme Activity in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease Patients Company Modifies Protocol for PROPEL Trial of PR001 for Parkinson’s Disease Patients with GBA1 Mutations; Expec...

NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chi...